Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis

Summary

Vitamin D and its analogs are currently widely used for the treatment of psoriasis. The study drug (CTA018) is a novel analog of vitamin D, and this Phase 2 study will investigate the efficacy and safety of CTA018 in the treatment of psoriasis. Patients with chronic plaque psoriasis will receive one of three doses of CTA018 cream or vehicle (no study drug) daily for 12 weeks.

Timeline

Start

2006-09

Primary completion

2007-05

Completion

2007-05

Drugs

Indications